KR830002567B1 - 퀴나졸린 유도체의 제조방법 - Google Patents
퀴나졸린 유도체의 제조방법 Download PDFInfo
- Publication number
- KR830002567B1 KR830002567B1 KR1019800001676A KR800001676A KR830002567B1 KR 830002567 B1 KR830002567 B1 KR 830002567B1 KR 1019800001676 A KR1019800001676 A KR 1019800001676A KR 800001676 A KR800001676 A KR 800001676A KR 830002567 B1 KR830002567 B1 KR 830002567B1
- Authority
- KR
- South Korea
- Prior art keywords
- chloroform
- quinazoline
- amino
- chloride
- piperazino
- Prior art date
Links
- 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 title claims 3
- 238000004519 manufacturing process Methods 0.000 title description 2
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 4
- 239000002253 acid Substances 0.000 claims description 19
- 150000003839 salts Chemical class 0.000 claims description 10
- 231100000331 toxic Toxicity 0.000 claims description 6
- 230000002588 toxic effect Effects 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 1
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 abstract description 20
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 abstract description 18
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 abstract description 5
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 abstract description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 abstract description 3
- 150000003246 quinazolines Chemical class 0.000 abstract description 2
- 238000001953 recrystallisation Methods 0.000 abstract description 2
- 239000012265 solid product Substances 0.000 abstract description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 abstract 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 13
- 238000000034 method Methods 0.000 description 8
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 150000001805 chlorine compounds Chemical class 0.000 description 3
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 3
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- -1 tarrate Chemical compound 0.000 description 3
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- NRQJIAVOKMKUOR-UHFFFAOYSA-N 2-piperazin-1-ylquinazoline Chemical compound C1CNCCN1C1=NC=C(C=CC=C2)C2=N1 NRQJIAVOKMKUOR-UHFFFAOYSA-N 0.000 description 2
- APKHJGDGWQDBGM-UHFFFAOYSA-N 6,7-dimethoxy-2-piperazin-1-ylquinazolin-4-amine Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N1CCNCC1 APKHJGDGWQDBGM-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- UDETZZKGDGINOX-UHFFFAOYSA-N [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(3,4-dihydro-2h-chromen-2-yl)methanone Chemical compound C1CC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 UDETZZKGDGINOX-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 2
- 239000012024 dehydrating agents Substances 0.000 description 2
- 229940093499 ethyl acetate Drugs 0.000 description 2
- 235000019439 ethyl acetate Nutrition 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 1
- QZVPHVMVWZKULP-UHFFFAOYSA-N 2,3-dihydro-1-benzofuran-2-carbonyl chloride Chemical compound C1=CC=C2OC(C(=O)Cl)CC2=C1 QZVPHVMVWZKULP-UHFFFAOYSA-N 0.000 description 1
- HCXJFMDOHDNDCC-UHFFFAOYSA-N 5-$l^{1}-oxidanyl-3,4-dihydropyrrol-2-one Chemical group O=C1CCC(=O)[N]1 HCXJFMDOHDNDCC-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 208000007530 Essential hypertension Diseases 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- SXDBWCPKPHAZSM-UHFFFAOYSA-M bromate Inorganic materials [O-]Br(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-M 0.000 description 1
- SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 125000005544 phthalimido group Chemical group 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- VBUBADWLHFZFDK-UHFFFAOYSA-N quinazoline;hydrochloride Chemical compound Cl.N1=CN=CC2=CC=CC=C21 VBUBADWLHFZFDK-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB7914431 | 1979-04-25 | ||
| GB14431 | 1979-04-25 | ||
| GB79.14431 | 1979-04-25 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR830002758A KR830002758A (ko) | 1983-06-30 |
| KR830002567B1 true KR830002567B1 (ko) | 1983-11-14 |
Family
ID=10504770
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019800001676A KR830002567B1 (ko) | 1979-04-25 | 1980-04-25 | 퀴나졸린 유도체의 제조방법 |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US4279910A (de) |
| JP (1) | JPS55145684A (de) |
| KR (1) | KR830002567B1 (de) |
| AR (1) | AR224400A1 (de) |
| AT (1) | AT373596B (de) |
| BE (1) | BE882967A (de) |
| CA (1) | CA1132558A (de) |
| CH (1) | CH642076A5 (de) |
| CS (1) | CS209950B2 (de) |
| DD (1) | DD150202A5 (de) |
| DE (1) | DE3015676A1 (de) |
| DK (1) | DK121080A (de) |
| EG (1) | EG14651A (de) |
| ES (1) | ES490867A0 (de) |
| FI (1) | FI64592C (de) |
| FR (1) | FR2455042A1 (de) |
| GB (1) | GB2049683B (de) |
| GR (1) | GR68049B (de) |
| HU (1) | HU184747B (de) |
| IE (1) | IE49705B1 (de) |
| IL (1) | IL59900A (de) |
| IT (1) | IT1141490B (de) |
| LU (1) | LU82394A1 (de) |
| NL (1) | NL182563C (de) |
| NO (1) | NO152508C (de) |
| NZ (1) | NZ193511A (de) |
| PH (1) | PH15156A (de) |
| PL (1) | PL121470B1 (de) |
| PT (1) | PT71139A (de) |
| SE (1) | SE435061B (de) |
| SU (1) | SU915804A3 (de) |
| YU (1) | YU41709B (de) |
| ZA (1) | ZA802488B (de) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3511836A (en) * | 1967-12-13 | 1970-05-12 | Pfizer & Co C | 2,4,6,7-tetra substituted quinazolines |
| US3663706A (en) * | 1969-09-29 | 1972-05-16 | Pfizer | Use of 2,4-diaminoquinazolines as hypotensive agents |
| US4026894A (en) * | 1975-10-14 | 1977-05-31 | Abbott Laboratories | Antihypertensive agents |
| US4001237A (en) * | 1976-02-18 | 1977-01-04 | Bristol-Myers Company | Oxazole, isoxazole, thiazole and isothiazole amides |
| US4140776A (en) * | 1977-09-16 | 1979-02-20 | Merck & Co., Inc. | N-pyrazinecarbonyl-N'-acylguanidines |
| GB2007656B (en) * | 1977-11-05 | 1982-05-19 | Pfizer Ltd | Therapeutic agents |
-
1980
- 1980-03-20 DK DK121080A patent/DK121080A/da not_active IP Right Cessation
- 1980-04-15 US US06/140,534 patent/US4279910A/en not_active Expired - Lifetime
- 1980-04-16 CS CS802656A patent/CS209950B2/cs unknown
- 1980-04-19 GR GR61722A patent/GR68049B/el unknown
- 1980-04-22 EG EG80247A patent/EG14651A/xx active
- 1980-04-23 DE DE19803015676 patent/DE3015676A1/de not_active Ceased
- 1980-04-23 IT IT21598/80A patent/IT1141490B/it active
- 1980-04-23 FI FI801306A patent/FI64592C/fi not_active IP Right Cessation
- 1980-04-23 AR AR280773A patent/AR224400A1/es active
- 1980-04-23 NZ NZ193511A patent/NZ193511A/xx unknown
- 1980-04-23 IL IL59900A patent/IL59900A/xx unknown
- 1980-04-23 AT AT0218980A patent/AT373596B/de not_active IP Right Cessation
- 1980-04-23 LU LU82394A patent/LU82394A1/fr unknown
- 1980-04-24 GB GB8013543A patent/GB2049683B/en not_active Expired
- 1980-04-24 ES ES490867A patent/ES490867A0/es active Granted
- 1980-04-24 SU SU802912149A patent/SU915804A3/ru active
- 1980-04-24 DD DD80220686A patent/DD150202A5/de unknown
- 1980-04-24 BE BE0/200366A patent/BE882967A/fr not_active IP Right Cessation
- 1980-04-24 IE IE827/80A patent/IE49705B1/en unknown
- 1980-04-24 CA CA350,598A patent/CA1132558A/en not_active Expired
- 1980-04-24 JP JP5485980A patent/JPS55145684A/ja active Granted
- 1980-04-24 PT PT71139A patent/PT71139A/pt unknown
- 1980-04-24 ZA ZA00802488A patent/ZA802488B/xx unknown
- 1980-04-24 SE SE8003122A patent/SE435061B/sv not_active IP Right Cessation
- 1980-04-24 FR FR8009235A patent/FR2455042A1/fr active Granted
- 1980-04-24 PH PH23945A patent/PH15156A/en unknown
- 1980-04-24 YU YU1131/80A patent/YU41709B/xx unknown
- 1980-04-24 CH CH317280A patent/CH642076A5/de not_active IP Right Cessation
- 1980-04-24 NL NLAANVRAGE8002387,A patent/NL182563C/xx not_active IP Right Cessation
- 1980-04-24 HU HU801016A patent/HU184747B/hu unknown
- 1980-04-24 NO NO801196A patent/NO152508C/no unknown
- 1980-04-25 PL PL1980223755A patent/PL121470B1/pl unknown
- 1980-04-25 KR KR1019800001676A patent/KR830002567B1/ko active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS6216944B2 (de) | ||
| EP0480071B1 (de) | S-(niedere fettsäuren)-substituierte glutathionderivate | |
| WO2023138541A1 (zh) | 吡啶酰胺类parp抑制剂、及其制备方法和医药用途 | |
| US5223488A (en) | Oxidized-type glutathione alkyl ester | |
| EP0350251B1 (de) | N-substituierte Amid-Derivate | |
| EP0351435B1 (de) | Kondensierte pyridazin-verbindungen und deren verwendung als arzneimittel | |
| KR830002567B1 (ko) | 퀴나졸린 유도체의 제조방법 | |
| EP0007441A1 (de) | N- (N-Acetyl-L-Methionyl) - 3,4 - diäthoxy-carbonyloxy-phenäthylamin, Verfahren zu dessen Herstellung und dieses Phenyläthylamin-Derivate enthaltende pharmazeutische Zusammensetzungen | |
| EP0180158A1 (de) | Eine Thiazinverbindung, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen | |
| EP0575890A1 (de) | Fumarsäure Salze von Chinolin Derivate zur Aufhebung von vielfacher Drogenresistenz in der Krebsbehandlung | |
| FR2460934A1 (fr) | Derives d'isoquinoleine contenant du soufre, procedes pour leur preparation et compositions pharmaceutiques les contenant | |
| GB2171997A (en) | 4-Amino-6,7-dimethoxy-2-Piperazin-1-ylquinazoline derivatives | |
| EP0226753B1 (de) | Alpha-tocopherol(halo)uridin-Diester von Phosphorsäure, deren Salze und Verfahren zu deren Herstellung | |
| EP0039919B1 (de) | Benzoxazol und Benzothiazol-Derivate mit antiallergischer Wirkung | |
| SK281980B6 (sk) | Kryštallický (+)l-hydrogenvínan, spôsob jeho prípravy, farmaceutický prostriedok s jeho obsahom a jeho použitie | |
| JPH0228152A (ja) | コレシストキニン拮抗薬 | |
| US4405633A (en) | Method of treatment of asthma | |
| JPH02191272A (ja) | １，５―ベンゾオキサチエピン誘導体 | |
| JP2001507711A (ja) | テトラゾリルベンゾピランの製法 | |
| US4874776A (en) | Compound having mucus regulating and elastase-inhibitory activities, for the therapy of pulmonal emphysema and pulmonal fibrosis | |
| JP3049284B2 (ja) | ヒダントイン誘導体並びにそれを有効成分とする糖尿病合併症及び循環器系疾患の予防及び治療剤 | |
| KR820001847B1 (ko) | 4-아미노-2-피페리디노퀴나졸린 유도체의 제조방법 | |
| EP0379737A2 (de) | Dihydropyridinderivate zur Behandlung von Angiospasmen | |
| US4230706A (en) | Antihypertensive quinazoline compounds | |
| US6706732B1 (en) | Nasal preparation of guanidinoimino quinoline derivatives |